桑国卫:临床试验应作为三甲医院评定金标准

2012-09-27 MedSci MedSci原创

“原来讲循证医学最时髦,现在全球几乎都在热议‘转化医学’,究竟转化医学与创新药有何关系?”2012年9月19日,桑国卫教授在第10届中国国际新药创制前沿技术与产业化发展峰会上,谈到了转化医学与创新药物的关系。 国家新药创制科技重大专项的技术总师,中国药理学会理事长、中国工程院院士桑国卫教授在峰会作“我国医药产业发展与药物创新战略”的主题报告 转化医学(Translational Medicin

“原来讲循证医学最时髦,现在全球几乎都在热议‘转化医学’,究竟转化医学与创新药有何关系?”2012年9月19日,桑国卫教授在第10届中国国际新药创制前沿技术与产业化发展峰会上,谈到了转化医学与创新药物的关系。 国家新药创制科技重大专项的技术总师,中国药理学会理事长、中国工程院院士桑国卫教授在峰会作“我国医药产业发展与药物创新战略”的主题报告 转化医学(Translational Medicine)又称为转化研究(Translational Research),是指通过从事生命科学的科学家、药学家与临床医生之间的合作,运用现代生命科学的手段与方法,研究并解决临床医学问题,或者更合理地设计与研发创新药物及检测药盒。转化医学是现代医学的重要内容,将加速生命科学成果应用,加速临床医学形成新模式,促进人民健康水平的提高。 桑国卫教授解读了转化医学周期,即实验室研究人员、临床医生及制药企业必须全力协作以设计更合理的药物来改善治疗效果。 图片来源:桑国卫教授现场报告截图 谈及到此,桑国卫教授提出了他个人建议,他认为要将临床实验(比如医疗器械、抗体、干细胞等临床实验)作为三甲医院评定的金标准,作为临床

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2041090, encodeId=b13a204109099, content=<a href='/topic/show?id=c2c59619965' target=_blank style='color:#2F92EE;'>#金标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96199, encryptionId=c2c59619965, topicName=金标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jan 05 16:23:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365827, encodeId=d994136582e8a, content=<a href='/topic/show?id=468119e04db' target=_blank style='color:#2F92EE;'>#三甲医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19704, encryptionId=468119e04db, topicName=三甲医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Sep 29 02:23:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552271, encodeId=a4ef15522e16d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Sat Sep 29 02:23:00 CST 2012, time=2012-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2041090, encodeId=b13a204109099, content=<a href='/topic/show?id=c2c59619965' target=_blank style='color:#2F92EE;'>#金标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96199, encryptionId=c2c59619965, topicName=金标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jan 05 16:23:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365827, encodeId=d994136582e8a, content=<a href='/topic/show?id=468119e04db' target=_blank style='color:#2F92EE;'>#三甲医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19704, encryptionId=468119e04db, topicName=三甲医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Sep 29 02:23:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552271, encodeId=a4ef15522e16d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Sat Sep 29 02:23:00 CST 2012, time=2012-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2041090, encodeId=b13a204109099, content=<a href='/topic/show?id=c2c59619965' target=_blank style='color:#2F92EE;'>#金标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96199, encryptionId=c2c59619965, topicName=金标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jan 05 16:23:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365827, encodeId=d994136582e8a, content=<a href='/topic/show?id=468119e04db' target=_blank style='color:#2F92EE;'>#三甲医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19704, encryptionId=468119e04db, topicName=三甲医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Sep 29 02:23:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552271, encodeId=a4ef15522e16d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Sat Sep 29 02:23:00 CST 2012, time=2012-09-29, status=1, ipAttribution=)]
    2012-09-29 陈吴1239